PDL Biopharma Overview
PDL Biopharma (PDLI) has a ROE of -23.02%, below the Healthcare sector average of 29.39%.
Get informed when a big investor buys or sells
+ Follow-23.02%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, PDLI shows a ROE of -23.02%. That is below the Healthcare sector average of 29.39%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 29.39%. PDL Biopharma is at -23.02%, which is lower that average. That is roughly 178.3% below the sector mean. Use the comparison chart on this page to see how PDLI stacks up against individual peers as well.
Check the historical chart to see whether PDLI's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare PDL Biopharma with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has PDL Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -23.02%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 29.39%, while PDLI is at -23.02%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
